Status:
COMPLETED
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
Lead Sponsor:
Forest Laboratories
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
Eligibility Criteria
Inclusion
- Male and female outpatients 18 to 80 years of age, self-identified as Hispanic or Latino ethnicity
- Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen
- Meet criteria for stage I or II hypertension
- Currently not treated, or being treated with no more than two anti-hypertensive medications
Exclusion
- Secondary hypertension
- Are taking three or more antihypertensive agents
- Have uncontrolled or poorly controlled diabetes mellitus type I or type II
- Evidence of other concurrent disease or conditions that might interfere with the conduct of the study
- Participation in any investigational study within 30 days of Screening (Visit 1).
- Have a history of hypersensitivity to nebivolol or other β-blockers, or any contraindication to β-blocker use
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
277 Patients enrolled
Trial Details
Trial ID
NCT00770861
Start Date
September 1 2008
Last Update
January 26 2011
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site
Buena Park, California, United States, 90620
2
Forest Investigative Site
Chino, California, United States, 91710
3
Forest Investigative Site
Long Beach, California, United States, 90806
4
Forest Investigative Site
Los Angeles, California, United States, 90057